Duality Biotherapeutics, Inc. risk profile
44 Elevated one input has moved against it
Measured 1 September 2026 from 4ZB's filed statements. Recomputed nightly.
44 (Elevated), driven by Market expectation at 80, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Stable | Drawdown from the 52-week high — 62.2% |
| Operating pressure | 43 | Elevated | Easing | Costs outgrowing revenue — +12.2 percentage points |
| Cash conversion | 23 | Normal | Worsening | Capital spending against operating cash — 0.07x |
| Leverage and coverage | 38 | Normal | Easing | Interest cover — -2,133.31x |
| Competitive position | 44 | Elevated | Stable | Operating-margin gap against peers — -27.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Duality Biotherapeutics, Inc.